Opinion|Videos|August 27, 2024
Choosing MDS Therapies: Risk-Based Approaches
Medical experts discuss risk-based approaches to choosing MDS therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide a high level overview of treatment approaches for both lower and higher risk MDS.
- What are the key considerations when selecting between different treatment options for lower risk MDS?
- Please include a discussion of when hypomethylating agents (HMAs) would be used in lower risk disease.
Advertisement
Related to this article
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
SURPASS-CVOT data show fewer deaths or HF events with tirzepatide vs dulaglutide in patients with HF, driven largely by mortality.
Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
3
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
4
Admilparant Phase 3 ALOFT-IPF Trial Meets Primary End Point in IPF
5